Gold nanoparticles in the diagnosis and treatment of ovarian and cervical cancers: a comprehensive understanding.

Colorimetry enables rapid ovarian cancer biomarker screening but suffers from limited resolution. Eda et al. circumvented this via smartphone-integrated analysis leveraging mobile imaging hardware advances (~40nm) ( 85 ). Alternatively, Hao et al. engineered Mg/Fe-layered double hydroxide nanoflowers as high-density AuNPs (~10nm, Rapid injection synthesis) carriers for lateral flow immunoassay (LFIA) ( 86 ). These porous templates achieve ultrahigh AuNPs loading, lowering HE4 detection to 50 pM ( 86 ). CA125 is the clinical gold standard for ovarian cancer serology. Current AuNP-based detection platforms vary primarily in electrode composition and surface modification strategies( Table 5 ), integrating AuNPs with carbon nanomaterials (graphene, CNTs), polymers (chitosan, polydopamine, PAMAM), or novel frameworks (MXenes, MOFs) to enhance nanoparticle density, antigen capture efficiency, and electron transfer kinetics. The integration of MOFs with AuNPs achieves reproducible CA12-specific recognition, demonstrating a RSD of 2.98% in repeatability experiments ( 87 ). Zahra’s MXene/GQD/AuNPs composite achieves a record LOD of 0.075nU/mL ( 88 ). DLS sensors offer the broadest linear range (5fg/mL~50ng/mL) for high-dynamic CA125 quantification ( 89 ), while AuNP-DNA fluorescence quenching enables continuous biomarker monitoring. Near-field communication (NFC) integration further streamlines data acquisition, enhancing clinical utility ( 90 ). Sensor design scheme for detecting CA125 based on AuNPs. Beyond CA125, AuNP-based sensors target biomarkers including p53, HE4, exosomes, and DNA methylation ( 91 , 103 – 106 ). Following Weiwei et al.’ s MOF-AuNPs for CA125 ( 95 ), Xu and team developed a sandwich electrochemical immunosensor using synergistic signal amplification between Prussian blue (PB) and thiolated ionic MOF composites (TIMO + F-KB@AuNPs) for HE4 quantification ( 107 ). The platform employs TIMO + F-KB@AuNPs as conductive sensing substrates for capture antibody (Ab 1 ) immobilization, while PB nanoparticles carry detection antibodies (Ab 2 ). HE4 binding forms an Ab 1 -HE4-Ab 2 -PB complex, generating electrochemical signals proportional to concentration (linear range: 0.1~80ng/mL, LOD: 0.02ng/mL) ( 107 ). Demonstrating high selectivity, reproducibility, and stability with 97.10~114.07% serum recovery, it enables early ovarian cancer diagnosis ( Figure 8 ). Separately, superparamagnetic CoFeB enhances AuNPs-based p53 detection (LOD: 0.006 U/mL) ( 104 ). Furthermore, exosomes predict ovarian cancer chemotherapy response. Meshach and team developed a cysteine-functionalized AuNP (Au-cys) biosensor using SERS to simultaneously capture cisplatin and small extracellular vesicles from biological samples, enabling concurrent early detection and treatment efficacy assessment ( 102 ). Shows the principle of the prepared electrochemical biosensor for fast detection of HE4 ( 107 ). (Copyright permission obtained). AuNPs facilitate ovarian cancer diagnosis via urine, exhaled gas, and cyst fluid analysis ( 108 , 109 ). Thomas and team pioneered nanopore sensing where AuNPs capture 13 cysteine-containing urinary peptides within α-hemolysin nanopores, generating distinct current signatures: stepwise reductions for small peptides versus polymorphic fluctuations for larger ones, enabling prolonged single-molecule characterization ( 108 ). AuNPs-based platforms also detect microbiome-derived Volatile organic compounds (VOCs) in exhaled breath with 82% screening accuracy ( 110 ). AuNPs drive transformative ovarian cancer imaging advances ( 19 ). Dheeraj and team engineered FA-targeted, hydrazinonicotinamide-chelated AuNPs enabling efficient 99mTc radiolabeling for tumor-specific single-photon emission computed tomography (SPECT) contrast ( 111 ). Further functionalization yielded GO/SPIO/AuNP composite sheets integrating PTT, radiotherapy, and MRI within a unified theranostic platform ( 112 ). MARS spectral photon-counting CT (SPCCT), though primarily preclinical, enables material-specific imaging via energy-dependent X-ray attenuation. Dhiraj et al. functionalized AuNPs with LHRH via PEG tethers for ovarian cancer targeting ( 113 ). Intraperitoneal administration in murine models achieved selective accumulation in peritoneal tumors (0.46~2.12ng/mg, ICP-MS). While current SPCCT sensitivity limited absolute quantification, it mapped gold distribution patterns ( 113 ). Increased LHRH density (3000~15000molecules/particle) enhanced targeting while maintaining >60% metabolic activity at therapeutic concentrations (12~30μg/mL), establishing a novel theranostic strategy ( 113 ). Functionalized AuNPs support ovarian cancer-specific detection via fluorescence lifetime imaging ( 114 ), dark-field ( 115 ), and confocal Raman microscopy ( 116 ). SERS imaging further enables chemoresistance prediction and survival outcome assessment ( 117 ). AuNPs enable targeted ovarian cancer drug delivery, enhancing dispersion or internalization of agents like linalool, cetuximab, paclitaxel, let-7a miRNA, and nidocarcinoma-derived factor( Table 6 ). DOX-AuNPs show superior tumor growth inhibition versus free doxorubicin while overcoming payload leakage limitations ( 118 ). Engineered for MICU1-targeting siRNA delivery, they achieve >85% silencing efficiency via lysosome evasion, addressing key shortcomings of conventional carriers ( 119 ). Design of AuNPs for the treatment of ovarian cancer (drug delivery). Antibody or peptide-conjugated AuNPs enable precise ovarian cancer targeting ( 128 ). Edison and team engineered FSH33-AuNPs covalently conjugated to tumor-suppressive miR-145 ( 122 ). This system protects miR-145 from degradation, mediates selective cancer cell internalization, and inhibits proliferation, migration, anchorage-independent growth, and VEGF secretion. AuNPs enable co-delivery of multiple therapeutic agents, as demonstrated by Tommaso et al. who engineered miR-200c and trastuzumab (TZ)-loaded nanoparticles that dual-target critical pathways driving SKOV3 cell survival and proliferation in vitro , overcoming TZ resistance while potentially improving therapeutic outcomes for HER2-positive ovarian cancer ( 126 ). Beyond antibody/peptide targeting, TME and hyperthermia trigger drug release from AuNPs ,123 . Reza et al. engineered antibody-conjugated magneto-gold composites (TXT@Fe 3 O 4 /PVA/Au-SORT) for ovarian cancer ( 28 ). Photothermal AuNPs heating dissociates the PVA matrix, achieving precise TXT release (94.4 ± 4.1% over 180 min in TME). Ca(OH) 2 pretreatment combined with TXT therapy enhanced intratumoral accumulation, inhibited migration, and induced DNA damage, achieving 78.3% tumor suppression with reduced systemic toxicity ( Figure 9 ). Confocal images of the subjected TXT@Fe3O4/PVA/Au nano-therapeutic to the stained cells. Green: HTB76 cancerous, and blue: NIH 3T3 fibroblast cells (106 DFU), in the presence of the individual TXT, TXT@Fe3O4/PVA/Au (Cargo), and TXT@Fe3O4/PVA/Au-SORT particles (Cargo-SORT) particles. Cell staining was performed using crystal violet, and incubation was carried out at 37 °C with 95% humidity for 2 hours. Pretreatment was done with Ca(OH)2@Fe3O4/PVA/Au-SORT particles in the same dosage with the TXT-containing therapeutic (10μg/mL) ( 28 ). Notably, AuNPs morphology critically influences therapeutic outcomes: anisotropic AuNPs@CSA-131 exhibit enhanced cytotoxicity against ovarian carcinoma versus spherical counterparts ( 124 ). Furthermore, AuNPs modulate drug presentation in vivo , facilitating theaflavin oxidation to cytotoxic quinone derivatives ( 125 ). Regarding therapeutic side effects, The triple-modality approach (ultrasound/AuNCs/cisplatin) overcomes cisplatin resistance in resistant ovarian cancer models, suggesting reduced chemotherapy side effects with translational potential ( 129 ). AuNPs inhibit ovarian carcinoma invasiveness by targeting key oncogenic pathways: impeding MAPK signaling, suppressing EMT-associated proteins, and disrupting the IGFBP2/mTOR/PTEN autoregulatory axis, downregulating IGFBP2, suppressing PI3K/AKT/mTOR activation, and reactivating PTEN ( 130 , 131 ). Current understanding posits that AuNPs disrupt multicellular TME communication (cancer cells, cancer-associated fibroblasts, endothelial cells), downregulating pro-tumorigenic cytokines and growth factors ( 132 , 133 ). Specifically, they reduce CC-secreted fibroblast-activating proteins (TGF-β1, PDGF, uPA, TSP1) and inhibit tumor angiogenesis by blocking VEGF-VEGFR2 signalling ( 133 , 134 ). This positions AuNPs as key tools for elucidating and disrupting pro-tumorigenic crosstalk. AuNPs synchronize disulfidptosis and ferroptosis in ovarian cancer by modulating the SLC7A11/GSH/GPX4 axis ( 135 ). The composite system exploits AuNPs’ glucose oxidase-like activity and Ap-mediated GLUT1 downregulation to induce metabolic crisis ( 135 ). Glucose deprivation limits NADPH replenishment, disrupting cystine/cysteine conversion and resolving the disulfidptosis-ferroptosis execution paradox. Concurrently, iron-based components deliver Fe² + while AuNPs-catalyzed glucose oxidation self-supplies H 2 O 2 , amplifying Fenton reactions and ferroptotic death ( 135 ). Beyond influencing signalling pathways, AuNPs enhance nuclear rigidity via perinuclear laminA/C overexpression, impeding cancer cell migration ( 136 ). Concurrently, they induce ROS-mediated apoptosis/autophagy, trapping cells in G0/G1 phase ( 137 ). Anisotropic AuNPs exert enhanced anti-migratory effects versus spherical counterparts ( 138 ). Analogous to cervical cancer applications, morphological engineering of AuNPs enhances their cytotoxic efficacy against ovarian cancer cells. Irfan et al. attribute this phenomenon to elongated-branched antibody-functionalized AuNPs effectively evading serum protein corona entrapment, thereby facilitating optimal aptamer binding to HER2 receptors on cancer cell surfaces ( 139 ). This mechanism induces significant cytotoxicity in HER2-overexpressing SKOV3 cells through targeted apoptosis initiation. AuNPs enable synergistic chemo-photothermal therapy for ovarian cancer ( 127 , 140 ). Yiting et al. engineered a genetically fused HSA nanocarrier (RHMH18@AuD) self-assembling via histidine hydrophobicity to encapsulate DTX while forming ultrasmall AuNPs through biomimetic mineralization ( 141 ). This 80-nm platform prevents HSA denaturation and reduces inorganic nanoparticle toxicity. MMP-2 cleavage at tumors releases RGD-HSA@Au (mediating photothermia) and His@DTX micelles, with acidic TME-triggered DTX release. The system demonstrated targeted cellular uptake, significant tumor suppression, and 100% survival at 70 days versus complete mortality in monotherapy groups by day 62, establishing a high-efficacy, low-toxicity therapeutic strategy. Diverse AuNPs composites serve as photothermal agents for ovarian cancer PTT. rGO-AuNPs-PEG exhibits strong SERS signals, NIR-II PA signals, and high photothermal efficiency in tumours under 1061 nm laser irradiation ( 142 ). Similarly, silica nanocapsules containing aggregated AuNPs yolk-shell structures (aAuYS) demonstrate enhanced photothermal effects with 808 nm laser exposure ( 143 ). Curcumin-incorporated gold nanoshells (Cur-AuNShs) show efficient photothermal conversion with potential for selective cancer targeting and treatment. Additionally, AuNPs morphology influences PTT efficiency ( 144 ). For instance, dumbbell-shaped Au-Fe 3 O 4 elevate thermal conversion efficacy ( 145 ). To overcome resolution limitations in image-guided PTT, Annan et al. developed ultra-small GnRHR-targeted AuNDs (Au-GRHa, 3.2nm) ( 146 ). Prepared via electrochemical displacement and ligand conjugation, these nanoconstructs enable dual-modal fluorescence/CT imaging with superior CT contrast (attenuation coefficient: 5.153cm²/g) and renal clearance. GnRHa targeting boosted SKOV3 cellular uptake by 76% versus non-targeted counterparts. Under 808 nm irradiation, localized temperatures reached 50 °C within 5 min, inducing apoptosis via membrane disruption and protein denaturation. In vivo peak tumor accumulation occurred at 2 h, with subsequent PTT significantly suppressing tumor growth without hemolysis or toxicity, establishing a precise image-guided therapeutic platform. PDT and PTT act synergistically against ovarian cancer. A multifunctional nanomicrogel (Au@MSN–Ter/THPP@CM@GelMA/CAT) demonstrates concurrent photodynamic efficacy (650nm) and photothermal ablation (980nm) ( 147 ). AuNPs exhibit radiosensitizing effects, exemplified by thioglucose-bound nanoparticles (Glu-GNPs) enhancing ovarian cancer radiotherapy ( 148 ). The GO-SPIO-Au nanoflower platform integrates graphene oxide (NIR-PTT), AuNPs (radiosensitization), and superparamagnetic iron oxide (MRI) for image-guided therapy ( 112 ). In murine models, combined PTT/RT yielded 1.85× and 1.44× higher efficacy than PTT or RT alone, respectively. Kinga et al. developed a novel cancer therapy combining antibody-drug conjugates (ADCs) with β-emitting ¹ 98 AuNPs conjugated to trastuzumab emtansine (T-DM1), demonstrating specific HER2 affinity and synergistic efficacy against HER2-overexpressing cancers at low T-DM1 doses (0.015~0.124μg/mL) with 10–20 MBq/mL radiation ( 149 ). Continuous 7-day treatment (20 MBq/mL+0.031μg/mL T-DM1) disrupted 3D tumor spheroids, suggesting potential for HER2-positive breast/ovarian cancer treatment despite preferential suitability of inorganic nanoradiopharmaceuticals for localized delivery ( Figure 10 ) ( 149 ). Microscopic images of the measured control and compound-treated SKOV-3 spheroids ( 149 ).

Cervical and ovarian cancers represent the most lethal gynecological malignancies, each posing distinct clinical challenges. HPV infection constitutes the primary etiological factor for most cervical carcinomas, thus establishing HPV testing as critical for early screening ( 1 ). Organized screening and HPV vaccination provide key prevention strategies, especially in developing nations ( 2 ). The protracted asymptomatic latency spanning decades from cervical intraepithelial neoplasia to invasive carcinoma creates significant fertility preservation challenges for reproductive-aged patients, given that radical hysterectomy remain primary therapeutic options ( 3 , 4 ). Ovarian cancer demonstrates the highest aggressiveness among gynecological malignancies, with its characteristically asymptomatic early-stage presentation resulting in fewer than 50% of patients surviving beyond five years post-diagnosis ( 5 , 6 ). Molecular heterogeneity, intrinsic chemoresistance, and rapid metastatic dissemination collectively contribute to its elevated mortality ( 7 ). Conventional strategies lack early precision and fail to prevent multidrug resistance, necessitating advanced approaches ( 8 , 9 ). With advancements in oncology, nanotechnology has emerged as a promising frontier ( 10 , 11 ). Therapeutically, multifunctional nanoparticle-based drug delivery platforms enable cancer cell-specific targeting while sparing healthy tissues, thereby reducing systemic drug exposure, minimizing toxicity, and delaying resistance emergence ( 12 – 14 ). Diagnostically, nanoparticles enhance tumor biomarker detection sensitivity, facilitating earlier clinical intervention ( 15 , 16 ). Among diverse nanomaterials, gold nanoparticles (AuNPs) stand out due to exceptional biocompatibility and their defining optical property ( 17 ). AuNPs are synthesized through established methods including the Turkevich citrate reduction, biological synthesis using plant/microbial extracts, and physical approaches like laser ablation, enabling precise control over size, morphology, and surface functionalization for biomedical applications ( 18 ). Localized Surface Plasmon Resonance (LSPR) arises from collective electron oscillations, generating intense, tunable absorption/scattering for colorimetric sensing and enabling Surface-enhanced Raman scattering (SERS) via electromagnetic “hot spots” for trace analyte detection ( 19 , 20 ). Critically, LSPR drives efficient light-to-energy conversion, underpinning AuNPs’ efficacy as potent photothermal agents and photosensitizers in photothermal therapy (PTT) and photodynamic therapy (PDT) ( 21 ). As the morphology progressively evolves, AuNPs’ amplified surface-area-to-volume ratio enhances biomolecular interactions, while exceptional electrical conductivity (>10 5 S/m for 20-nm particles) facilitates ultrasensitive detection ( 18 , 22 , 23 ). LSPR “hot spots” also modulate fluorescence and enable fluorescence resonance energy transfer (FRET) ( 24 ). AuNPs’ surfaces are readily functionalized via covalent conjugation, biomolecular assembly, or polymeric encapsulation (e.g., thiol anchoring, amide bonds, click chemistry, electrostatic adsorption) to confer targeting specificity, colloidal stability, and multifunctionality ( 25 , 26 ). This enables active targeting (antibodies/peptides/aptamers) ( 27 ) or passive magnetic guidance (Fe 3 O 4 composites) ( 28 ), allowing their use as multimodal contrast agents (MRI/X-ray/OCT) ( 29 ). Furthermore, AuNPs exhibit distinct catalytic activity in redox reactions, enabling applications in electrochemical biosensors ( 30 ). Collectively, these physicochemical properties underpin AuNPs’ transformative potential in diagnosing and treating gynecological malignancies. Collectively, AuNPs represent a pivotal milestone in precision medicine, offering transformative potential for timely cancer intervention. The following sections detail the application of AuNPs, critically evaluating their contributions to diagnosing and treating gynecological malignancies to establish a reference framework for clinical practice.

Despite being a promising nanomaterial, AuNPs must overcome several significant barriers prior to broad clinical adoption for diagnosing and treating gynecological malignancies. The safety profile of AuNPs represents a modifiable property, critically dependent on factors such as particle size, synthesis method, exposure route, dosage duration, and the specific biological milieu ( 150 , 151 ). In numerous studies cited above, AuNPs are often assumed to be chemically inert and stable materials, particularly when PEG-modified, exhibiting negligible toxicity at certain doses. Merely 28 investigations to date have employed MTT assays and related techniques to evaluate the cytotoxicity of novel functionalized AuNPs toward normal cells or animal models. In the clinical context of managing gynecological malignancies, chemotherapy is typically a protracted process ( 152 ). Repeated administration of functionalized AuNPs during such long-term treatment carries a significant risk of inducing antibodies against the nanoparticle surface characteristics. This immunogenic response could potentially compromise the targeting efficacy of AuNPs and disrupt normal immune function. Furthermore, diverse AuNPs synthesis and functionalization strategies can leave toxic chemical residues on the particle surfaces. These modifications also alter the chemical properties and size of the AuNPs, potentially hindering renal clearance and leading to progressive bioaccumulation. Additionally, compared to free drugs, administering chemotherapeutic nanoparticles during ovulation increases ovarian toxicity and reduces fertility ( 153 ). Therefore, the menstrual cycle warrants consideration in the design and implementation of AuNPs therapies for female patients. These concerns underscore the necessity for further comprehensive evaluation of AuNPs systemic safety in humans and detailed investigation into nanoparticle pharmacokinetics to fully assess their absorption, distribution, metabolism, and excretion processes. Addressing AuNP safety challenges requires systematic pharmacokinetic studies (absorption, distribution, metabolism, excretion) in animal models to define critical thresholds for nanoparticle-induced irreversible organ damage, enabling establishment of dimensionally-, morphologically-, and synthesis-method-dependent safety dosage windows across varied administration regimens. Green synthesis strategies utilizing novel catalysts demonstrate promising toxicological safety profiles, potentially representing key advancement pathways ( 75 , 76 ). Multifunctional AuNPs may shorten chemotherapy cycles while combined PTT and PDT therapies could circumvent antibody responses from chronic treatment ( 127 , 141 ). Nevertheless, large-scale animal validation remains indispensable; current maximum reported cohort sizes of 28 subjects prove insufficient, particularly given physiological disparities between rodent and human systems, necessitating expansion to rabbit and non-human primate models. These imperatives collectively emphasize comprehensive assessment of systemic AuNP safety in humans and rigorous pharmacokinetic investigation. The diagnostic and therapeutic efficacy of AuNPs requires further validation. The majority of studies demonstrating potential benefits are confined to cell lines or small animal models, overlooking the substantial complexity of human physiology. In cervical cancer diagnostics, merely 15 of 34 peer-reviewed investigations disclosed clinical sample accuracy (n=9) or spiked serum analyte recovery (n=6), with two HPV detection reports achieving >95% accuracy in cohorts exceeding 100 specimens. Regarding therapeutic applications, only 2 of 15 cervical cancer publications documented AuNP efficacy in murine models. Similarly, among 28 ovarian cancer diagnostic analyses, 18 provided clinical validation data (n=4) or serum recovery metrics (n=14), though clinical specimens numbered ≤10 per analysis. Whereas 21 of 28 therapeutic investigations asserted significant antitumor outcomes, merely 9 confirmed efficacy in animal models with quantification parameters undisclosed. Humans are continuously exposed throughout life to diverse natural and anthropogenic nanoparticles. Such environmental nanoparticle contamination constitutes a significant exogenous interference factor, potentially impeding the function of administered AuNPs. For instance, titanium or iron oxide nanoparticles can inhibit cancer cell uptake of AuNPs ( 154 ). Beyond these exogenous factors, endogenous human variables also critically influence AuNPs performance. Evidence indicates that elevated cholesterol levels and specific lipid ratios disrupt the delivery capacity of DOX-AuNPs systems ( 155 ). Even in Phase III clinical trials, AuNPs-based drug delivery systems demonstrated suboptimal recognition efficiency for ovarian cancer, with the majority of intratumoral nanoparticles becoming either trapped within the extracellular matrix or sequestered by perivascular tumor-associated macrophages ( 156 ). Compounding these issues, many studies report human validation based on single-digit sample cohorts, lacking comparison with healthy individuals or non-gynecological cancer patients, and frequently omit detailed accuracy data ( Supplementary Material 1 ). Subsequent investigations must validate AuNPs’ true diagnostic-therapeutic efficacy through large-scale animal models and clinical trials, with priority assessment of their resistance to complex biological interferences including protein corona formation and lipid adsorption. Although functionalized AuNPs demonstrate anti-interference capabilities in select studies, the disparity between simulated laboratory conditions and physiological environments necessitates rigorous in vivo verification. Novel non-spherical geometries such as high-aspect-ratio nanostars effectively circumvent protein corona shielding while enhancing tumor targeting precision ( 139 ). Notably, nanoparticles within the 10~20 nm size range exhibit optimal performance, yet synthesis-dependent variations in AuNP dimensions/morphologies demand standardized evaluation frameworks to enable cross-study comparability and collaborative advancement. Furthermore, addressing prevalent data limitations stemming from insufficient clinical samples requires establishing multicenter validation frameworks. AuNPs’ therapeutic potential should transcend conventional drug delivery roles toward multimodal theranostic platforms, exemplified by triple-modality regimens integrating PTT, controlled chemotherapeutic release, and radiosensitization, with concurrent treatment monitoring via PAI and PET-CT. While four diagnostic investigations have incorporated machine learning for enhanced SERS-based high-throughput chip detection, deep learning applications in medical image interpretation remain unexplored. Integrating big data analytics with mobile health technologies could establish intelligent diagnostic networks to reduce misinterpretation risks. Finally, the cost implications of AuNPs systems demand serious consideration. In resource-limited developing nations, economic constraints remain pivotal in restricting large-scale disease screening initiatives. Most current studies fail to address the cost structure of AuNPs-based diagnostic platforms, with only a handful reporting screening expenses or reusability metrics ( 157 ). A predominant focus on novel materials and intricate architectures, particularly acute within the domain of AuNPs-designed electrochemical sensors, often overshadows the underlying premise of screening: low cost and high accessibility. Furthermore, AuNPs synthesis methodologies themselves represent significant cost determinants, compounded by concerns regarding environmental impact and suboptimal production efficiency ( 151 ). These factors establish cost as a paramount consideration for the clinical translation of AuNPs technologies. The convergence of artificial intelligence and low-cost smartphones offers a significant pathway to reduce expenditures associated with AuNP-based diagnostic systems, effectively lowering human resource requirements, time costs, and sample transport losses. Implementing a three-tier diagnostic network comprising colorimetric detection units, subject mobile client devices, and hospital data centres substantially enhances population screening efficiency. A core advantage of this system lies in the capacity for AI algorithms to perform localized processing directly on smartphones, enabling preliminary screening and interpretation of test results; only data indicating anomalies require transmission to the hospital data centre for verification, thereby markedly alleviating the healthcare burden in resource-limited settings. This tiered network fundamentally transforms the traditional hierarchical “hospital-centric–healthcare worker–subject” information delivery model. By empowering subjects with autonomous testing capabilities, it shifts the paradigm from passive information reception to proactive health management, significantly improving participant engagement and adherence. From a technological development perspective, research efforts should recalibrate their focus regarding AuNPs: prioritizing material design optimization that establishes an optimal cost-accuracy balance over the pursuit of increasingly complex material combinations; directing energy towards developing scalable, low-power manufacturing processes; and advancing clinical integration through modular designs that reduce the overall system cost. Notably, clinical trials of AuNPs in gynaecological malignancies remain limited. However, recent human studies across non-gynaecological cancers, spanning breast cancer, colorectal carcinoma and cutaneous disorders, demonstrate expanding clinical evaluation ( 158 – 162 ). These advances confirm that current implementation challenges are addressable and reveal diagnostic and therapeutic benefits warranting further translation in gynaecological oncology. Collectively, AuNPs systems exhibit significant potential for enhancing diagnostic accuracy, improving patient quality of life, and optimizing clinical prognoses. Looking forward, their unique physicochemical properties position AuNPs as transformative agents in next-generation gynecologic oncology, enabling minimally invasive theranostics, real-time disease monitoring, and personalized treatment regimens. Continued advancements in nanomaterial engineering, refined targeting methodologies, comprehensive safety evaluations, and integration of AI further solidify AuNPs platforms to assume an increasingly critical and expansive role in future integrated theranostic frameworks ( Figure 11 ). Current diagnostic and therapeutic approaches utilizing AuNPs in cervical and ovarian cancers, and associated challenges and future prospects.

AuNPs serve as pivotal components in multimodal theranostic platforms owing to their distinctive physicochemical properties, enabling visualized precision therapy of pathological lesions. Diversified therapeutic strategies demonstrate that targeted accumulation of AuNPs at disease sites generates synergistic effects, with imaging guidance being critical for maximizing diagnostic-therapeutic efficacy. Current research has developed functionalized AuNPs-based visualization approaches for gynecological malignancies. Zhang’s team overcame single-modality imaging limitations by establishing a PAI/CT/MRI multimodal system centered on functionalized AuNPs, effectively addressing the low X-ray attenuation coefficient inherent to inorganic materials ( 67 ). At 200 µg/mL, Au-UCNPs-DSPE-PEG precisely delineated cervical cancer location, dimensions and morphological characteristics in murine models, while their photothermal conversion capability simultaneously enabled photoacoustic imaging-guided combination photothermal and photodynamic therapy ( 67 ). Beyond physical modalities, AuNPs function as chemotherapeutic carriers. Taheri et al. employed CT to monitor TXT@AuNPs distribution for efficacy assessment, yet single-modality CT proved inadequate for tracking drug release kinetics ( 28 ). Wang’s team addressed this through multimodal imaging (PAI/FL/CT) for real-time surveillance of drug-loaded AuNPs. Paclitaxel release induced fluorescence signal fluctuations due to AuNP surface restructuring while accelerating nanoparticle metabolic clearance, consequently reducing photoacoustic intensity in lesions ( 123 ). For quantitative release monitoring, Yim’s team innovatively leveraged AuNPs’ low X-ray attenuation property ( 66 ). Electrostatic adsorption-triggered aggregation of radioiodinated AuNPs, occurring through opposite surface charges after DOX release, significantly enhanced lesion signals on PET-CT imaging ( 66 ). These aggregates maintained prolonged high-signal states due to extended half-life, enabling sustained dynamic observation.

Clinical management of gynecological malignancies faces significant challenges, including difficulties in early detection, high therapeutic resistance, substantial risks of residual disease post-surgery, and considerable toxicity from conventional radiotherapy and chemotherapy. These critical limitations demand innovative technological solutions for precision diagnostics and therapeutics. Recent advances in nanotechnology provide transformative momentum for gynecologic oncology, with AuNPs offering particularly promising strategies due to their tunable dimensions, morphological versatility, customizable surface functionalization, and unique optical properties. AuNPs serve as highly sensitive contrast agents that enhance detection rates for early-stage lesions and micrometastases. Functionalization with antibodies, peptides, or aptamers enables precise targeting of therapeutic payloads to disease sites and facilitates ultrasensitive detection of trace biomarkers in liquid biopsies. Furthermore, their exceptional photothermal conversion efficiency and photochemical capabilities permit concurrent targeted chemotherapy with spatially precise photothermal and photodynamic therapy at tumor sites. This integrated theranostic approach positions AuNPs-based systems to drive a paradigm shift from isolated interventions toward closed-loop precision management in gynecologic oncology. Nevertheless, further validation remains imperative to address clinical translation barriers and long-term safety profiles.